

What does NIH do for global health R&D?

The National Institutes of Health (NIH) advances basic, applied, and clinical research across a range of global health areas and products. NIH facilitates this research through in-house programs and grants to universities, nonprofits, and other organizations and operates clinical trial networks that serve as the backbone for clinical trials taking place across America and the world.


Why is NIH's role in global health R&D important?

NIH is the United States' leading medical research institution and a respected, world-class scientific powerhouse. Its work to advance research for global infectious diseases, through the National Institute of Allergy and Infectious Diseases; to coordinate crosscutting HIV/AIDS research, through the Office of AIDS Research; and to strengthen international research capacity, through the Fogarty International Center, forms the building blocks for future drugs, vaccines, diagnostics, and other tools that save and improve lives around the world.

NIH support has helped advance:

99 promising products in late-stage development

R&D investment by health area



2017-2021 data. Abbreviations: TB: Tuberculosis. EIDs: Emerging infectious diseases. NTDs: Neglected tropical diseases. Sexual & reproductive health other than HIV/AIDS.

IMPACT OF INVESTMENT

HIV/AIDS

Development of the first **antiretroviral drugs** and other subsequent therapies, which have collectively averted an estimated **12.1 million AIDS-related deaths** since 2010.

TB

Development of a **new drug for highly drug-resistant tuberculosis (TB)**, which is part of a combination regimen that has **reduced treatment time** from up to two years to six months while dramatically improving outcomes.

NTDs

Development of **drugs to treat neglected tropical diseases (NTDs)**, including a low-cost treatment for visceral leishmaniasis and novel drugs for sleeping sickness and Chagas disease.

DIARRHEAL DISEASE

Creation of **two low-cost rotavirus vaccines** manufactured in India, ROTAVAC and ROTASIIL, that are now in use in several countries worldwide.

CAPACITY STRENGTHENING

The Fogarty International Center has provided **research training** to more than **7,500 US and foreign scientists** working in low- and middle-income countries, including alumni who have played vital roles in the Ebola, Zika, COVID-19, and HIV/AIDS responses.

COVID-19

Development of **COVID-19 vaccines**, including those from Moderna, AstraZeneca/Oxford, and Johnson & Johnson.